Background Factors Contributing to Safety Warning Discordance in the Initial Labeling of New Drugs in Japan, the United States, and the European Union

Ähnliche Einträge

• Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies
  von: Mihoko Kobayashi, et al.
  Veröffentlicht: (2025)
• Comparison of Population Pharmacokinetics‐Related Information in Drug Labeling Between Japan, the United States, and the European Union
  von: Kei Fukuhara, et al.
  Veröffentlicht: (2025)
• Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
  von: Enrico Costa, et al.
  Veröffentlicht: (2026)
• A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies
  von: Sachiko Mita, et al.
  Veröffentlicht: (2026)
• Comparative Analysis of Post‐Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023
  von: Diana Mandslay, et al.
  Veröffentlicht: (2024)